• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 464174 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414803306 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414803306 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Regeneron Pharmaceuticals Crosses Below its 10-day MA (REGN)

Published on Thu, 03/21/2013 - 11:12
By Robert Cotter

Regeneron Pharmaceuticals (NASDAQ:REGN) shares have crossed bearishly below their 10-day moving average of $172.67 on a volume of 135K shares. Swing traders may find an opportunity for a short position, as such a crossover often suggests lower prices in the near term.

Regeneron Pharmaceuticals share prices have moved between a 52-week high of $188.95 and a 52-week low of $42.83 and are now trading 302% above that low price at $172.30 per share. Over the past week, the 200-day moving average (MA) has gone up 0.4% while the 50-day MA has declined 0.3%.

Potential upside of 9.1% exists for Regeneron Pharmaceuticals, based on a current level of $172.30 and analysts' average consensus price target of $188.00. The stock should discover initial support at its 50-day moving average (MA) of $170.88 and subsequent support at its 200-day MA of $152.65.

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.

By Robert Cotter
rcotter@fnno.com

Latest News from FNNO

Zimmer Looks to Continue to Trade Above ...

Shares of Zimmer (NYSE:ZMH) traded today at $111.21, breaking its 52-week high. This n ...

Shares of Yahoo! Rise to a New 52-Week H...

Yahoo! (NASDAQ:YHOO) traded at a new 52-week high today of $46.52. So far today approx ...

Shares of Aqua America Rise to a New 52-...

Shares of Aqua America (NYSE:WTR) traded at a new 52-week high today of $26.42. This n ...

West Pharmaceutical Services: 52-Week Hi...

Shares of West Pharmaceutical Services (NYSE:WST) traded today at $51.63, breaking its ...

Recent 52-Week High Exceeded in Shares o...

Shares of WesBanco (NASDAQ:WSBC) traded at a new 52-week high today of $34.94. This ne ...

Recent 52-Week High Exceeded in Shares o...

Weingarten Realty Investors (NYSE:WRI) traded at a new 52-week high today of $36.02. S ...

Shares of WR Berkley Rise to a New 52-We...

WR Berkley (NYSE:WRB) traded today at a new 52-week high of $51.63. This new high was ...

VCA Antech: 52-Week High Recently Eclips...

Shares of VCA Antech (NASDAQ:WOOF) traded at a new 52-week high today of $45.94. So fa ...